Der er ADA2026 (American Diabetes Association) konference i weekenden. Pfizer har sendt en semi-interessant pressemeddelelse ud. Ellers synes jeg det indtil videre forventligt har vaeret lidt smaat med nyheder sammenlignet med ADA2025.
Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer's GLP-1 RA Berobenatide
https://www.pfizer.com/news/press-release/press-release-detail/robust-phase-2b-efficacy-and-favorable-tolerability-support
Den stoerste nyhed fra ADA2026 er desvaerre den her:
Police Remove Diabetes Experts From Conference for Distributing Critique of Trump Administration
https://www.nytimes.com/2026/06/05/well/ada-conference-diabetes-trump.html
First They Came / Als sie kamen ...
---
Nedenfor pressemeddelelser fra de andre. Jeg kan ikke se, at Roche har sendt noget ud:
https://www.roche.com/media/releases
People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more likely to achieve greater than 5% weight loss than those who were switched to tirzepatide, in real-world data
https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916561
Novo Nordisk's investigational zenagamtide shows significant HbA1C reductions with up to 14.6% weight loss in adults with type 2 diabetes - presented at ADA 2026
https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916559
Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications
https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-drove-substantial-improvements
New data from Phase 2 ZUPREME-1 trial at the American Diabetes Association 2026 Scientific Sessions further support potential of petrelintide to redefine the weight management experience for people living with overweight and obesity
https://www.globenewswire.com/news-release/2026/06/05/3307625/0/en/New-data-from-Phase-2-ZUPREME-1-trial-at-the-American-Diabetes-Association-2026-Scientific-Sessions-further-support-potential-of-petrelintide-to-redefine-the-weight-management-expe.html
Web cast fra Novo Nordisk her natten mellem soendag og mandag:
https://edge.media-server.com/mmc/p/xxkg9u3t/
Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer's GLP-1 RA Berobenatide
https://www.pfizer.com/news/press-release/press-release-detail/robust-phase-2b-efficacy-and-favorable-tolerability-support
Den stoerste nyhed fra ADA2026 er desvaerre den her:
Police Remove Diabetes Experts From Conference for Distributing Critique of Trump Administration
https://www.nytimes.com/2026/06/05/well/ada-conference-diabetes-trump.html
First They Came / Als sie kamen ...
---
Nedenfor pressemeddelelser fra de andre. Jeg kan ikke se, at Roche har sendt noget ud:
https://www.roche.com/media/releases
People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more likely to achieve greater than 5% weight loss than those who were switched to tirzepatide, in real-world data
https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916561
Novo Nordisk's investigational zenagamtide shows significant HbA1C reductions with up to 14.6% weight loss in adults with type 2 diabetes - presented at ADA 2026
https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916559
Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications
https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-drove-substantial-improvements
New data from Phase 2 ZUPREME-1 trial at the American Diabetes Association 2026 Scientific Sessions further support potential of petrelintide to redefine the weight management experience for people living with overweight and obesity
https://www.globenewswire.com/news-release/2026/06/05/3307625/0/en/New-data-from-Phase-2-ZUPREME-1-trial-at-the-American-Diabetes-Association-2026-Scientific-Sessions-further-support-potential-of-petrelintide-to-redefine-the-weight-management-expe.html
Web cast fra Novo Nordisk her natten mellem soendag og mandag:
https://edge.media-server.com/mmc/p/xxkg9u3t/
7/6 2026 21:21 bb8 0
132638 Boehringer Ingelheim's survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting improved metabolic health in people living with obesity
https://www.boehringer-ingelheim.com/human-health/metabolic-diseases/survodutide-phase-3-fat-loss-obesity-dual-agonist-data
https://www.boehringer-ingelheim.com/human-health/metabolic-diseases/survodutide-phase-3-fat-loss-obesity-dual-agonist-data
